GSK Announced US FDA Approved Priorix To Prevent Measles, Rubella and Mumps
GSK Plc. Announced that, the Food and Drug Administration (FDA) of the United States has now approved Priorix for the active immunisation to prevent the individuals from measles, mumps and rubella (MMR), which are 12 months of age and older. Priorix has currently been licenced in over 100 countries across the world including all the […]
Continue Reading